Diabetes type 2
Conditions
Interventions
Theptarin hospital
Ramathibodi hospital
Maharaj Nakorn Chaing Mai
Treatment
Investigator
Sponsors
AstraZeneca Thailand Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Outpatient ≥ 18 years of age 2. Diagnosis of T2DM prior to the first prescription of SGLT2i 3. First prescription for SGLT2i between October 2014 and end of available of Ramathibodi, Chiang Mai University and Theptarin hospital data in April 2018, receiving SGLT2i at least 3 months.
Exclusion criteria
Exclusion criteria: 1. Hypersensitivity to any SGLT2 inhibitor or any of the components in the formulation 2. Patients with other type of diabetes ie. Type 1 DM, gestational diabetes, etc 3. Patient who use SGLT2i for obesity indication 4. Severe medical condition that in the view of the investigator prohibits participation in the study e.g .cancer, end stage liver disease 5. Renal Function :<45 ml/min/1.73m²
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Description of patient characteristics at baseline, HbA1c, Weight and Blood pressure at baseline and day 0, month 3, month 6, month 12, month 18, month 24, month 30, month 36, month 42 or last consulta HbA1c, Weight and Blood pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| Other lab parameters For FPG and hypoglycemia day 0, 3, 6, 12, 18, 24, 30, 36, 48 and last visit. Others, day 0 and LV FPG, Lipid change, serum creatinine, eGFR, reaching goal proportion, hypoglycemia | — |
Contacts
Public ContactYotsapon Thewjitcharoen
Theptarin
Outcome results
None listed